Skip to content
Parakho

Q1 FY27, unaudited

Revenue
₹109.07 Cr
Profit after tax
₹21.04 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations109.07+11.80%407.29
Other income3.81+117.95%8.99
Total income112.89+13.67%416.28
Employee benefit expense29.42+5.76%114.41
Finance costs0.24−24.76%1.17
Depreciation & amortisation12.55+27.24%43.77
Total expenses84.55+14.18%310.71
Profit before tax28.34+12.18%103.95
Tax expense7.30+14.57%26.44
Profit after tax21.04+11.37%77.51
Total comprehensive income21.03+11.33%77.45
Earnings per share
Earnings per share, basic₹4.71₹17.40
Earnings per share, diluted₹4.66₹17.20

Q1 FY27 unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base unaudited, from the company’s filing with NSE. Source

FY26 from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Vimta Labs reported Q1 FY27 total income of INR1,129 million, up 13.7% year-on-year, with EBITDA of INR411 million and PAT of INR210 million. Management said pharma contract research and testing grew year-on-year while food testing declined due to weaker import-export sample receipts linked to global trade challenges. The company secured and onboarded its first Biologics services order during the quarter and outlined an approximately INR80 crore capex plan for FY27.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 38 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 21 Aug 2026.